Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0116 | 0.5907 | 0.5907 |
Echinococcus granulosus | a disintegrin and metalloproteinase with | 0.0075 | 0.314 | 1 |
Brugia malayi | MH2 domain containing protein | 0.0116 | 0.5907 | 0.5731 |
Loa Loa (eye worm) | angiogenesis inhibito | 0.0028 | 0.0052 | 0.0052 |
Onchocerca volvulus | Papilin homolog | 0.0056 | 0.1938 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0056 | 0.1938 | 0.1938 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0049 | 0.1429 | 0.1429 |
Loa Loa (eye worm) | hypothetical protein | 0.0051 | 0.1596 | 0.1596 |
Brugia malayi | ADAMTS-like protease | 0.0055 | 0.1833 | 0.148 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0049 | 0.1429 | 0.106 |
Loa Loa (eye worm) | hypothetical protein | 0.0049 | 0.1429 | 0.1429 |
Schistosoma mansoni | ADAMTS5 peptidase (M12 family) | 0.0075 | 0.314 | 1 |
Echinococcus multilocularis | a disintegrin and metalloproteinase with | 0.0075 | 0.314 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0049 | 0.1429 | 0.106 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.0414 | 0.0414 |
Brugia malayi | angiogenesis inhibito | 0.0055 | 0.1833 | 0.148 |
Brugia malayi | hypothetical protein | 0.0051 | 0.1596 | 0.1234 |
Loa Loa (eye worm) | hypothetical protein | 0.0179 | 1 | 1 |
Schistosoma mansoni | adam (A disintegrin and metalloprotease | 0.0051 | 0.1596 | 0.4338 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0116 | 0.5907 | 0.5907 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 162.1 uM | Inhibition of Escherichia coli primase by scintillation proximity assay | ChEMBL. | 17350255 |
MIC (functional) | > 64 ug ml-1 | Antibacterial activity against Escherichia coli | ChEMBL. | 17350255 |
MIC (functional) | > 64 ug ml-1 | Antibacterial activity against Escherichia coli | ChEMBL. | 17350255 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.